A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

Exclusion criteria

• ✕. Any T-cell redirecting treatment (e.g., CD3-directed bispecific or Chimeric Antigen Receptor T-cell \[CAR-T\] therapy) within 90 days prior to the first dose of study treatment
• ✕. Immune checkpoint inhibitors within 6 weeks prior to the first dose of study treatment
• ✕. Radium (Ra) 223 dichloride within 28 days prior to the first dose of study treatment
• ✕. Any prior treatment with kallikrein-related peptidase 2 (KLK2)-targeted therapy
• ✕. Any prior prostate-specific membrane antigen (PSMA)-targeting therapy (that is \[i.e.\], participants who received PSMA-targeting radioconjugates are excluded) \[Parts 2A and 2B only\]. Prior PSMA RLT is allowed in Part 1 and required for Part 2C and Part 2D but last dose must be \>3 months prior to the first dose of study treatment
• ✕. Any prior antibody drug conjugates (ADCs) with microtubule inhibitor payloads (e.g., auristatins, maytansinoids, tubulysins)